TY - JOUR
T1 - TGF-β1 calcium signaling increases α5 integrin expression in osteoblasts
AU - Nesti, Leon J.
AU - Caterson, E. J.
AU - Wang, Mark
AU - Chang, Richard
AU - Chapovsky, Felix
AU - Hoek, Jan B.
AU - Tuan, Rocky S.
N1 - Funding Information:
This work is supported in part by the NIH (DE11327, DE16864, AR44501, AA08714, AA07186, AA07215) and the Annenberg Foundation. LJN is a recipient of NIH M.D.-Ph.D. NRSA (F30AA05516). The authors thank Drs. Marla Steinbeck, Suresh K. Joseph, J. Bruce Smith, and Noreen Hickok, for helpful discussions; and to Paul Anderson, for assistance in imaging assistance and analysis.
PY - 2002
Y1 - 2002
N2 - TGF-β is a potent osteoactive factor and exhibits a wide variety of effects on osteoblasts, most of which are mediated through receptor associated Smad proteins. We have recently reported a novel TGF-β intracellular Ca2+ signaling pathway in osteoblasts, and found that this signaling is required for the TGF-β1 mediated enhancement of osteoblast adhesion to substrate. Given that interaction between the extracellular matrix protein fibronectin and α5β1 integrin on the cell surface is principally responsible for osteoblast substrate adhesion, we examined here whether the TGF-β1 stimulated Ca2+ signal is involved in this pathway. Our results show that, in primary human osteoblasts, the TGF-β1 induced intracellular Ca2+ signal is responsible, in part, for the stimulation of expression of α5 integrin, but not of β1 integrin or fibronectin. Increased levels of α5 integrin protein and mRNA were seen as early as 12 h after TGF-β1 treatment, but were inhibited by co-treatment of cells with nifedipine, a selective L-type Ca2+ channel blocker. TGF-β1 treatment increased both fibronectin and β1 integrin protein production within 48 h, in a manner unaffected by co-treatment with nifedipine. Immunofluorescence observations revealed that TGF-β1 treatment resulted in increased α5 integrin staining, and more prominent α5 integrin clustering, with increased co-localization with the actin cytoskeleton, effects that were blocked by co-treatment with nifedipine. The TGF-β1 induced intracellular Ca2+ signal in human osteoblasts is thus an important mechanistic step in the regulation of α5 integrin expression, later contributing to enhanced cell adhesion.
AB - TGF-β is a potent osteoactive factor and exhibits a wide variety of effects on osteoblasts, most of which are mediated through receptor associated Smad proteins. We have recently reported a novel TGF-β intracellular Ca2+ signaling pathway in osteoblasts, and found that this signaling is required for the TGF-β1 mediated enhancement of osteoblast adhesion to substrate. Given that interaction between the extracellular matrix protein fibronectin and α5β1 integrin on the cell surface is principally responsible for osteoblast substrate adhesion, we examined here whether the TGF-β1 stimulated Ca2+ signal is involved in this pathway. Our results show that, in primary human osteoblasts, the TGF-β1 induced intracellular Ca2+ signal is responsible, in part, for the stimulation of expression of α5 integrin, but not of β1 integrin or fibronectin. Increased levels of α5 integrin protein and mRNA were seen as early as 12 h after TGF-β1 treatment, but were inhibited by co-treatment of cells with nifedipine, a selective L-type Ca2+ channel blocker. TGF-β1 treatment increased both fibronectin and β1 integrin protein production within 48 h, in a manner unaffected by co-treatment with nifedipine. Immunofluorescence observations revealed that TGF-β1 treatment resulted in increased α5 integrin staining, and more prominent α5 integrin clustering, with increased co-localization with the actin cytoskeleton, effects that were blocked by co-treatment with nifedipine. The TGF-β1 induced intracellular Ca2+ signal in human osteoblasts is thus an important mechanistic step in the regulation of α5 integrin expression, later contributing to enhanced cell adhesion.
UR - http://www.scopus.com/inward/record.url?scp=0036025218&partnerID=8YFLogxK
U2 - 10.1016/S0736-0266(02)00020-7
DO - 10.1016/S0736-0266(02)00020-7
M3 - Article
C2 - 12382972
AN - SCOPUS:0036025218
SN - 0736-0266
VL - 20
SP - 1042
EP - 1049
JO - Journal of Orthopaedic Research
JF - Journal of Orthopaedic Research
IS - 5
ER -